We are live on
!
Find out more
NR
Newfound Research Portfolio holdings
AUM
$40.8M
Turnover
15.49%
1-Year Est. Return
12.42%
This Fund
S&P 500
This Quarter
Est. Return
+11.46%
1 Year Est. Return
-12.42%
3 Year Est. Return
+54.59%
5 Year Est. Return
+89.01%
10 Year Est. Return
–
AUM
$38.9M
AUM Growth
+$3.87M
(+11%)
Cap. Flow
+$1.51M
Cap. Flow
% of AUM
3.88%
Top 10 Holdings %
Top 10 Hldgs %
70.48%
Holding
171
New
61
Increased
64
Reduced
1
Closed
45
Avg Time Held
0.2
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$9.08M |
| 2 |
JPMorgan US Momentum Factor ETF
JMOM
|
+$3.57M |
| 3 |
Fidelity Momentum Factor ETF
FDMO
|
+$2.82M |
| 4 |
iShares MSCI USA Momentum Factor ETF
MTUM
|
+$2.82M |
| 5 |
iShares MSCI USA Quality Factor ETF
QUAL
|
+$878K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$2.1M |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$2.09M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$2.09M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.09M |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$2.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 69% |
| 2 | Healthcare | 8.17% |
| 3 | Technology | 6.16% |
| 4 | Consumer Staples | 4.89% |
| 5 | Industrials | 4.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ALXN
76
DELISTED
Alexion Pharmaceuticals
ALXN
| $106K | 0.27% |
+680
| New | +$87.4K |
2020 Q4
0 quarters
|
|
77
Linde
LIN
$229B
| $103K | 0.27% |
+391
| New | +$96K |
2020 Q4
0 quarters
|
|
78
CoStar Group
CSGP
$12.9B
| $102K | 0.26% |
1,100
+670
| +156% | +$58.7K |
2020 Q3
1 quarter
|
|
79
Cintas
CTAS
$84.4B
| $102K | 0.26% |
+1,156
| New | +$100K |
2020 Q4
0 quarters
|
|
80
Icahn Enterprises
IEP
$4.7B
| $99K | 0.25% |
+1,953
| New | +$99.4K |
2020 Q4
0 quarters
|
|
81
Meta Platforms (Facebook)
META
$1.8T
| $98K | 0.25% |
360
+207
| +135% | +$56.7K |
2020 Q3
1 quarter
|
|
82
Jack Henry & Associates
JKHY
$10.6B
| $95K | 0.24% |
586
+437
| +293% | +$69.4K |
2020 Q3
1 quarter
|
|
83
Factset
FDS
$10.6B
| $94K | 0.24% |
+284
| New | +$93.9K |
2020 Q4
0 quarters
|
|
84
S&P Global
SPGI
$126B
| $90K | 0.23% |
+273
| New | +$92.1K |
2020 Q4
0 quarters
|
|
85
Medtronic
MDT
$121B
| $89K | 0.23% |
+758
| New | +$83.4K |
2020 Q4
0 quarters
|
|
86
Tyler Technologies
TYL
$14.7B
| $89K | 0.23% |
205
+130
| +173% | +$53.6K |
2020 Q3
1 quarter
|
|
87
Ametek
AME
$56.6B
| $88K | 0.23% |
+728
| New | +$82K |
2020 Q4
0 quarters
|
|
88
DELISTED
Electronic Arts
EA
| $85K | 0.22% |
593
+354
| +148% | +$45.6K |
2020 Q3
1 quarter
|
|
89
ResMed
RMD
$33.5B
| $85K | 0.22% |
398
+229
| +136% | +$45.7K |
2020 Q3
1 quarter
|
|
90
W.W. Grainger
GWW
$62.3B
| $84K | 0.22% |
+205
| New | +$80.6K |
2020 Q4
0 quarters
|
|
91
Danaher
DHR
$161B
| $82K | 0.21% |
418
+223
| +114% | +$44.7K |
2020 Q3
1 quarter
|
|
92
Thermo Fisher Scientific
TMO
$254B
| $82K | 0.21% |
175
+93
| +113% | +$43.6K |
2020 Q3
1 quarter
|
|
93
Bristol-Myers Squibb
BMY
$124B
| $79K | 0.2% |
+1,281
| New | +$78.8K |
2020 Q4
0 quarters
|
|
94
Mondelez International
MDLZ
$81.4B
| $79K | 0.2% |
+1,347
| New | +$77K |
2020 Q4
0 quarters
|
|
95
Dollar General
DG
$29.6B
| $78K | 0.2% |
372
+229
| +160% | +$48.9K |
2020 Q3
1 quarter
|
|
96
Cable One
CABO
$42.8M
| $71K | 0.18% |
+32
| New | +$63.3K |
2020 Q4
0 quarters
|
|
97
Insulet
PODD
$9.8B
| $65K | 0.17% |
254
+120
| +90% | +$29.8K |
2020 Q3
1 quarter
|
|
98
Rollins
ROL
$16B
| $64K | 0.16% |
1,642
+685
| +72% | +$26.5K |
2020 Q3
1 quarter
|
|
99
Equifax
EFX
$18.8B
| $62K | 0.16% |
+322
| New | +$54.1K |
2020 Q4
0 quarters
|
|
|
TIF
100
DELISTED
Tiffany & Co.
TIF
| $61K | 0.16% |
466
+281
| +152% | +$36K |
2020 Q3
1 quarter
|
|
Similar funds
AM
PSCM
HLC
LCM
MCMI
OMS
SEM
PIM
Newfound Research's Q4 2020 Portfolio in Review
As of Q4 2020, Newfound Research held 171 positions worth $38.9M, up 11% from $35M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Newfound Research deployed $1.51M of net new capital in Q4 2020, opening 61 new positions and adding to 64 existing holdings. Its largest new stake was JPMorgan US Momentum Factor ETF: 97,159 shares worth $3.78M.
By sector, the portfolio is most concentrated in Miscellaneous at 69% of assets, down from 92% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Cadence Design Systems, an estimated $2.93K trimmed.
- Newfound Research's largest Q4 2020 buy was JPMorgan US Momentum Factor ETF: 97,159 shares worth $3.78M.
- Newfound Research added most to State Street SPDR S&P 500 ETF Trust in Q4 2020, an estimated $9.08M increase.
- Newfound Research's biggest Q4 2020 reduction was Cadence Design Systems, cutting an estimated $2.93K.
- Newfound Research fully exited State Street Health Care Select Sector SPDR ETF in Q4 2020, selling an estimated $2.1M.
- Newfound Research's ten largest holdings make up 70% of its $38.9M portfolio in Q4 2020.
- Newfound Research opened 61 new positions and closed 45 in Q4 2020.
- Newfound Research's portfolio value rose 11% quarter-over-quarter to $38.9M.
Based on Newfound Research's 13F filing for Q4 2020, filed 22 Jan 2021.